How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,273 results for

Topical Hemostatic Agent

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Efficacy of Hemocoagulase as a Topical Hemostatic Agent After Dental Extractions: A Systematic Review (Full text)

Efficacy of Hemocoagulase as a Topical Hemostatic Agent After Dental Extractions: A Systematic Review Extraction is one of the more common oral surgical procedures carried out in routine dental practice, and postextraction bleeding is a recognized, frequently encountered complication. It causes distress, agony, and discomfort to the patient. The aim of this systematic review was to analyze the existing literature and determine the efficacy of topical hemocoagulase as a hemostatic agent and its (...) that compared topical hemocoagulase with saline pressure pack in patients requiring extraction of teeth were selected for review. Literature abstracts and full-text articles were analysed in this review. A total of four articles were included in this systematic review. All were randomized clinical trials that evaluated the clinical outcomes of topical hemocoagulase compared with saline pressure packs in extraction socket sites. A significant difference was present between the hemocoagulase group and control

2018 Cureus PubMed

2. The Use of Topical Hemostatic Agents in Cardiothoracic Surgery. (PubMed)

The Use of Topical Hemostatic Agents in Cardiothoracic Surgery. Topical hemostatic agents are used in conjunction with conventional procedures to reduce blood loss. They are often used in cardiothoracic surgery, which is particularly prone to bleeding risks. Variation in their use exists because detailed policy and practice guidelines reflecting the current medical evidence have not been developed to promote best surgical practice in this setting. To address this need, the Society (...) for the Advancement of Blood Management convened an International Hemostatic Expert Panel. This article reviews the available literature and sets out evidence-based recommendations for the use of topical hemostatic agents in cardiothoracic surgery.Copyright © 2017 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

2017 Annals of Thoracic Surgery

3. TETIS study: evaluation of new topical hemostatic agent TT-173 in tooth extraction. (PubMed)

TETIS study: evaluation of new topical hemostatic agent TT-173 in tooth extraction. TT-173 is a new hemostatic agent consisting of yeast-derived microvesicles containing a modified version of recombinant human tissue factor. In the present work, the procoagulant activity of TT-173 has been evaluated for the first time in humans.This is a phase I, randomized, placebo-controlled study to evaluate the efficacy, safety, systemic absorption, and immunogenicity of TT-173 in healthy volunteers (...) topical hemostatic agent in more complex oral surgeries and in those patients affected with coagulation disorders that may compromise the realization of dental procedures.The new hemostatic agent TT-173 has proven efficacious and safe in healthy subjects undergoing tooth extraction supporting its further evaluation in more complex surgeries.The development of this new topical hemostatic agent could contribute to bleeding control in oral and maxillofacial surgery.

2017 Clinical oral investigations

4. Hemostatic Agents Reduce Bond Strength in Class V Restorations

Hemostatic Agents Reduce Bond Strength in Class V Restorations UTCAT3069, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Hemostatic Agents Reduce Bond Strength in Class V Restorations Clinical Question In a healthy patient with a Class V carious lesion, does the use of retraction cord soaked with a hemostatic agent negatively impact the adhesion of the composite when compared to retraction cord with no hemostatic (...) agent? Clinical Bottom Line For patients with carious lesions adjacent to the gingival tissues, the bond strength of both total-etch and self-etch adhesives are reduced when the tooth structure has been contaminated by hemostatic agents. This finding is supported by a systematic review of in vitro studies as well as additional lab studies. The effect has been demonstrated with statistical significance with both types of adhesives, but the review contends that the effect is smaller with the total

2016 UTHSCSA Dental School CAT Library

5. Cardiac Emboli Documented by Intraoperative Transesophageal Echocardiogram During Administration of a Topical Hemostatic Agent Prior to Pedicle Subtraction Osteotomy. (PubMed)

Cardiac Emboli Documented by Intraoperative Transesophageal Echocardiogram During Administration of a Topical Hemostatic Agent Prior to Pedicle Subtraction Osteotomy. This is a case report.Describe the occurrence of cardiac emboli recorded on transesophageal echocardiogram (TEE) after the injection of a topical hemostatic agent into a vertebra prior to performing a pedicle subtraction osteotomy (PSO).Hemostasis during spinal surgery is critical for adequate visualization and to reduce the risk (...) of perioperative complications. Adult spinal deformity surgery can involve performing PSOs which are useful in cases of fixed spinal deformities and are associated with increased blood loss secondary to epidural and cancellous bleeding. Prior to performing a PSO, a topical hemostatic agent can be injected into the vertebra through the pedicle screw pilot holes in an attempt to decrease cancellous bleeding. Injected hemostatic agents can pressurize the vertebral body similar to cementation in vertebroplasty

2016 Spine

6. Comparison of Topical Hemostatic Agents in a Swine Model of Extremity Arterial Hemorrhage: BloodSTOP iX Battle Matrix vs. QuikClot Combat Gauze (Full text)

Comparison of Topical Hemostatic Agents in a Swine Model of Extremity Arterial Hemorrhage: BloodSTOP iX Battle Matrix vs. QuikClot Combat Gauze BloodSTOP iX Battle Matrix (BM) and QuikClot Combat Gauze (CG) have both been used to treat traumatic bleeding. The purpose of this study was to examine the efficacy and initial safety of both products in a swine extremity arterial hemorrhage model, which mimics combat injury. Swine (37.13 ± 0.56 kg, NBM = 11, NCG = 9) were anesthetized

2016 International journal of molecular sciences PubMed

7. Topical Hemostatic Agent

Topical Hemostatic Agent Topical Hemostatic Agent Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Topical Hemostatic Agent Topical (...) Hemostatic Agent Aka: Topical Hemostatic Agent , Hemostatic Agents II. Mechanism Topical Hemostatic Agents III. Indications Significant Bleeding Indicated for rapid non-extremity bleeding not controlled with direct manual pressure IV. Precautions Newer agents (Chitosan, and mineral dressings) are not widely available Primarily found in military and large s as of 2013 Risk of wound contamination with hemostatic agent (may require later debridement) V. Preparations: Agent Types Factor Concentrators (drying

2018 FP Notebook

8. A systematic review on the use of topical hemostats in trauma and emergency surgery. (Full text)

A systematic review on the use of topical hemostats in trauma and emergency surgery. A wide variety of hemostats are available as adjunctive measures to improve hemostasis during surgical procedures if residual bleeding persists despite correct application of conventional methods for hemorrhage control. Some are considered active agents, since they contain fibrinogen and thrombin and actively participate at the end of the coagulation cascade to form a fibrin clot, whereas others to be effective (...) require an intact coagulation system. The aim of this study is to provide an evidence-based approach to correctly select the available agents to help physicians to use the most appropriate hemostat according to the clinical setting, surgical problem and patient's coagulation status.The literature from 2000 to 2016 was systematically screened according to PRISMA [Preferred Reporting Items for Systematic Reviews and Meta-Analyses] protocol. Sixty-six articles were reviewed by a panel of experts

2018 BMC Surgery PubMed

9. HESTAT: Study protocol for a phase II/III, randomized, placebo-controlled, single blind study to evaluate the new hemostatic agent TT-173 in total knee arthroplasty. (PubMed)

HESTAT: Study protocol for a phase II/III, randomized, placebo-controlled, single blind study to evaluate the new hemostatic agent TT-173 in total knee arthroplasty. Several hemostatic treatments intended to reduce the bleeding associated to total knee arthroplasty have been investigated with varying degrees of success. TT-173 is a new topical agent based on recombinant tissue factor that activates the extrinsic pathway of coagulation. This trial aim is to evaluate the efficacy and safety of TT

2018 Contemporary clinical trials

10. EHTIC study: Evaluation of a new hemostatic agent based on tissue factor in skin grafting procedures. (PubMed)

EHTIC study: Evaluation of a new hemostatic agent based on tissue factor in skin grafting procedures. Excessive bleeding is a major concern in scar debridement and grafting procedures. TT-173 is a new topical hemostatic agent based on recombinant human tissue factor that has shown promising results in patients who underwent tooth extraction. EHTIC study sought to evaluate the efficacy and safety of TT-173 to reduce the bleeding in donor sites of skin grafting procedures.EHTIC study was a phase (...) period in all the patients that received TT-173. In contrast, 24.24% of patients from placebo group required additional measures to arrest hemorrhage (Fisher p=0.0013). Product related adverse events, systemic absorption into blood stream, interferences with the healing of the donor site or immunogenic reaction against TT-173 were not observed.The new hemostatic agent TT-173 has proven efficacious and safe to reduce the bleeding from donor site. This study paves the way for further investigation

2018 Burns : journal of the International Society for Burn Injuries

11. Rectal Misoprostol as a Hemostatic Agent During Abdominal Myomectomy

Rectal Misoprostol as a Hemostatic Agent During Abdominal Myomectomy Rectal Misoprostol as a Hemostatic Agent During Abdominal Myomectomy - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Rectal Misoprostol (...) as a Hemostatic Agent During Abdominal Myomectomy The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03064568 Recruitment Status : Recruiting First Posted : February 27, 2017 Last Update Posted : November 2, 2018 See Sponsor

2017 Clinical Trials

12. Analysis of Hemostatic Agents Compared to Physiologic Hemostasis

Analysis of Hemostatic Agents Compared to Physiologic Hemostasis Analysis of Hemostatic Agents Compared to Physiologic Hemostasis - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Analysis of Hemostatic (...) . Louis University Study Details Study Description Go to Brief Summary: This study is a prospective comparison between absorbable hemostatic agents as a group and the body's natural hemostatic ability without aid of therapy in patients undergoing bilateral sinus surgery with or without septoplasty. Condition or disease Intervention/treatment Phase Rhino Sinusitis Device: Arista Device: Nexafoam Device: Sinufoam Device: Nasopore Device: Posisep Hemostat Dressing Device: Posisep X Hemostat Dressing

2017 Clinical Trials

13. Availability and use of hemostatic agents in prehospital trauma patients in Pennsylvania translation from the military to the civilian setting (Full text)

Availability and use of hemostatic agents in prehospital trauma patients in Pennsylvania translation from the military to the civilian setting To understand the translation of one innovation in trauma care from the military to the civilian setting, the adoption of topical hemostatic agents in the Emergency Medical Services (EMS) community and in Trauma Centers in Pennsylvania.We utilized an anonymous electronic survey of EMS Agency Administrative Officers and Trauma Center Coordinators.We (...) with the application of the products and the indications for their use.Our survey found that 46.6% of the respondents indicated they carry hemostatic products, a much greater number than found on prior surveys of EMS agencies. There is a steady acceptance by EMS of new innovations in trauma care although more work is needed in translating the exact role of hemostatic agents in the civilian setting.

2017 Open access emergency medicine : OAEM PubMed

14. A Gelatin-Thrombin Matrix Topical Hemostatic Agent (Floseal) in Combination With Harmonic Scalpel Is Effective in Patients Undergoing Total Thyroidectomy: A Prospective, Multicenter, Single-Blind, Randomized Controlled Trial. (Full text)

A Gelatin-Thrombin Matrix Topical Hemostatic Agent (Floseal) in Combination With Harmonic Scalpel Is Effective in Patients Undergoing Total Thyroidectomy: A Prospective, Multicenter, Single-Blind, Randomized Controlled Trial. Hemostasis during thyroidectomy is essential; however, the safest, most efficient, and most cost-effective way to achieve this is unclear. This randomized, multicenter, single-blind, prospective study evaluated the efficacy and safety of using different hemostatic (...) + HS group compared with standard thyroidectomy. Floseal + HS also had a shorter surgery time (P < .0001) versus the other 3 treatments.Floseal + HS can be effective at reducing postsurgical drain output and provides a complementary hemostatic approach in patients undergoing total thyroidectomy.© The Author(s) 2015.

2015 Surgical innovation PubMed

15. Cardiac Emboli Documented by Intra-Operative Trans-Esophageal Echocardiogram (TEE) During Administration of a Topical Hemostatic Agent Prior to Pedicle Subtraction Osteotomy (PSO). (PubMed)

Cardiac Emboli Documented by Intra-Operative Trans-Esophageal Echocardiogram (TEE) During Administration of a Topical Hemostatic Agent Prior to Pedicle Subtraction Osteotomy (PSO).

2015 Spine

16. Topical hemostatic agents and dressings in the prehospital setting. (PubMed)

Topical hemostatic agents and dressings in the prehospital setting. Death from exsanguinating hemorrhage remains a priority in the management of combat casualties and civilian trauma patients with truncal and junctional injuries. Appropriate use of hemostatic agents and dressings in the prehospital setting may allow for earlier control and an improved survival rate.Third-generation chitosan-based hemostatic agents and dressings appear to be equally efficacious to the dressing currently deployed (...) by the US military forces in the management of hemorrhage not amenable to tourniquet placement. Unfortunately, a lack of clinical trials places a heavy reliance on anecdotal reports and laboratory studies in agent selection and application.Efficacy of currently available hemostatic agents and dressings appears to have plateaued in recent years although new agents and delivery mechanisms under development may improve control in cases of severe hemorrhage.

2015 Current Opinion in Anaesthesiology

17. Safety and Performance Evaluation of the Topical Hemostatic Device (AC5â„¢) Following Excision of Skin Lesions

Posted : August 7, 2018 Last Update Posted : August 7, 2018 Sponsor: ARCH Therapuetics Information provided by (Responsible Party): ARCH Therapuetics Study Details Study Description Go to Brief Summary: This study is designed to monitor patient safety after excision of skin lesions and subsequent application of AC5 topical hemostatic agent and to assess the performance of AC5 for controlling bleeding in skin wounds. Condition or disease Intervention/treatment Phase Skin Neoplasms Device: AC5 Topical (...) of a topical hemostatic agent (AC5) to a freshly excised skin lesion Device: AC5 Topical Hemostatic Device Randomized application of the hemostatic agent AC5 to one of two freshly excised lesions in each patient Placebo Comparator: Control The intervention in this arm is the application of saline (Control) to a freshly excised skin lesion Device: AC5 Topical Hemostatic Device Randomized application of the hemostatic agent AC5 to one of two freshly excised lesions in each patient Outcome Measures Go

2016 Clinical Trials

18. A self-controlled comparative clinical trial to explore the effectiveness of three topical hemostatic agents for stopping severe epistaxis in pediatrics with inherited coagulopathies. (PubMed)

A self-controlled comparative clinical trial to explore the effectiveness of three topical hemostatic agents for stopping severe epistaxis in pediatrics with inherited coagulopathies. The aim of this study was to assess the effectiveness of localized treatments to persistently stop epistaxis in patients with inherited bleeding disorders.In a self-controlled comparative clinical trial, to offer the best solution to stop epistaxis at home (within 10 minutes), patients with inherited bleeding (...) disorders were treated using three different topical hemostatic agents, including Tranexamic acid impregnated tampon, EpiCell tampon prepared from oxidized regenerated cellulose pad, and ChitoHem tampon (reinforced with chitosan). The results of using these different products on three groups of randomly selected patients were ultimately compared using the χ(2) and Fisher's exact test statistics.A total of 31 patients, 5 females and 26 males with a mean age of 5.6 years, were included in the study

2014 Hematology (Amsterdam, Netherlands)

19. Use of topical hemostatic agents in gynecologic surgery. (PubMed)

Use of topical hemostatic agents in gynecologic surgery. Sutures, hemoclips, and electrocautery are the primary mechanisms used to achieve hemostasis during gynecologic surgery, but in situations in which these are inadequate or not feasible, an array of hemostatic agents are available to help achieve hemostasis. These agents include physical agents such as cellulose, collagen, or gelatin products as well as biologic agents such as thrombin and fibrin products. Limited data are available (...) on many of these agents, although their use is increasing, sometimes at high costs. In gynecologic surgery, hemostatic agents are likely most effective when used in areas of oozing or slow bleeding and as an adjunct to conventional surgical methods of hemostasis.

2014 Obstetrical & Gynecological Survey

20. Effect of the plant-based hemostatic agent Ankaferd Blood Stopper® on the biocompatibility of mineral trioxide aggregate. (Full text)

of 56 Wistar-Albino rats were divided randomly and equally into two groups (MTA and MTA-ABS) according to whether or not a hemostatic agent was used. The remaining 16 rats were designated as the control group. Rats in the experimental groups received freshly mixed MTA-Angelus in polyethylene tubes, which were inserted into monocortical bore holes created in their tibias. In the MTA-ABS group only, 0.5 mL of ABS solution was administered topically on the defect sites followed by implantation of MTA (...) Effect of the plant-based hemostatic agent Ankaferd Blood Stopper® on the biocompatibility of mineral trioxide aggregate. Due to the detrimental effect of blood contamination on the physico-chemical properties of mineral trioxide aggregate (MTA), obtaining an effective hemostasis in the surgical crypt during apical surgery is of paramount importance. The purpose of this in vivo study was to analyze the effect of Ankaferd Blood Stopper® (ABS) contamination on the biocompatibility of MTA.Forty

2016 BMC Oral Health PubMed

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>